Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.34 |
| ▸ | NQO2 | P16083 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244250 | 0.84 | CYP3A4 (0.49) | TRPV1MEN1KMT2ACYP3A4 | |
| SCHEMBL3244247 | 0.84 | CYP3A4 (0.49) | TRPV1MEN1KMT2ACYP3A4 | |
| SCHEMBL6832562 | 0.80 | KDM1A (0.35) | CYP19A1TRPV1MEN1NPC1MAPT | |
| SCHEMBL10134577 | 0.78 | CYP3A4 (0.51) | CYP19A1NQO2MEN1NPC1MAPT | |
| SCHEMBL6832594 | 0.77 | CYP19A1 (0.36) | CYP19A1NQO2TRPV1MEN1NPC1 | |
| SCHEMBL5065601 | 0.72 | PDE3B (0.47) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL6832606 | 0.68 | PTGS1 (0.33) | CYP19A1KDM1A | |
| SCHEMBL2489133 | 0.67 | CYP3A4 (0.49) | TRPV1CYP3A4 | |
| SCHEMBL6832550 | 0.67 | GPR84 (0.34) | CYP19A1CYP3A4 | |
| SCHEMBL1543237 | 0.65 | CYP3A4 (0.68) | TRPV1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | CYP19A1 776/4885NQO2 269/4885TRPV1 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.